Publications by authors named "Daniel Norris"

Claim this Profile
A
Author Correction: Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Daniel A Norris

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling.
Xiang Gao, John K Diep, Daniel A Norris, Rosie Z Yu, Richard S Geary

Expert Opin Drug Metab Toxicol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma.
Yumi Yamamoto, Patricia Sanwald Ducray, Marcus Björnsson, Kevin Smart, Paul Grimsey, Daniel A Norris

CPT Pharmacometrics Syst Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Catherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, Everard G B Vijverberg, Peter Paul De Deyn, Daniel A Norris

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
Charles A Thornton, Richard Thomas Moxley, Katy Eichinger, Chad Heatwole, Laurence Mignon, Daniel A Norris

Lancet Neurol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Michael Monine, Daniel Norris, Yanfeng Wang, Ivan Nestorov

J Pharmacokinet Pharmacodyn· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration.
Paymaan Jafar-Nejad, Berit Powers, Armand Soriano, Hien Zhao, Daniel A Norris

Nucleic Acids Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.
Daniel M Ramos, Constantin d'Ydewalle, Vijayalakshmi Gabbeta, Amal Dakka, Stephanie K Klein, Daniel A Norris

J Clin Invest· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
Daniel A Norris, Noah Post, Rosie Z Yu, Sarah Greenlee, Yanfeng Wang

Bioanalysis· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Daniel A Norris

N Engl J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2018 White Paper on Recent Issues in Bioanalysis: 'A global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)' (Part 1 - small molecule regulated bioanalysis, small molecule biomarkers, peptides & oligonucleotide bioanalysis).
Jan Welink, Yuanxin Xu, Eric Yang, Amanda Wilson, Neil Henderson, Daniel A Norris

Bioanalysis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
Konstantinos Biliouris, Puneet Gaitonde, Wei Yin, Daniel A Norris, Yanfeng Wang

CPT Pharmacometrics Syst Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc-Conjugated 2'-MOE-ASOs.
Colby S Shemesh, Rosie Z Yu, Mark S Warren, Michael Liu, Mirza Jahic, Daniel A Norris

Mol Ther Nucleic Acids· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Kenneth T Luu, Daniel A Norris, Rudy Gunawan, Scott Henry, Richard Geary

J Clin Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the diversity and richness of understory bryophytes at Nectandra Cloud Forest Reserve, Costa Rica.
Daniel H Norris, Ekaphan Kraichak, Allen C Risk, Diane Lucas, Dorothy J Allard

Biodivers Data J· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Richard S Finkel, Claudia A Chiriboga, Jiri Vajsar, John W Day, Jacqueline Montes, Daniel A Norris

Lancet· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Claudia A Chiriboga, Kathryn J Swoboda, Basil T Darras, Susan T Iannaccone, Jacqueline Montes, Daniel A Norris

Neurology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
Richard S Geary, Daniel Norris, Rosie Yu, C Frank Bennett

Adv Drug Deliv Rev· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.
Rosie Z Yu, John S Grundy, Scott P Henry, Tae-Won Kim, Daniel A Norris

Mol Ther Nucleic Acids· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.
Frank Rigo, Seung J Chun, Daniel A Norris, Gene Hung, Sam Lee

J Pharmacol Exp Ther· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
Sebastien A Burel, So-Ri Han, Hong-Soo Lee, Daniel A Norris, Byoung-Seok Lee

Nucleic Acid Ther· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Timothy M Miller, Alan Pestronk, William David, Jeffrey Rothstein, Ericka Simpson, Daniel A Norris

Lancet Neurol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans.
Nicholas R Jones, Melissa A Pegues, Mark A McCrory, Walter Singleton, Claudette Bethune, Daniel A Norris

Mol Ther Nucleic Acids· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
David A Ellis, Julie K Blazel, Chinh V Tran, Frank Ruebsam, Douglas E Murphy, Daniel A Norris

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Douglas E Murphy, Chinh V Tran, Lian-Sheng Li, Jingjing Zhao, Daniel A Norris

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis